Analyst Jason McCarthy from Maxim Group maintained a Buy rating on OS Therapies Incorporated and keeping the price target at $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy’s rating is based on the promising results from OS Therapies’ Phase 2b trial for their OST-HER2 treatment in recurrent osteosarcoma. The trial demonstrated a significant improvement in event-free survival rates at 12 months, with 35% of patients achieving this milestone compared to 20% in historical controls, indicating a positive efficacy profile.
Additionally, the safety data was favorable, with no severe treatment-associated adverse events leading to discontinuation. The company has also made strides in regulatory progress by submitting preliminary external control data to the FDA, which could expedite the approval process. The potential for accelerated approval and the significant unmet medical need in this area further support the Buy rating, as does the possibility of obtaining a priority review voucher, which could be financially beneficial.
According to TipRanks, McCarthy is an analyst with an average return of -22.0% and a 26.71% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Brainstorm Cell Therapeutics, and TuHURA Biosciences.
In another report released on June 30, Lake Street also maintained a Buy rating on the stock with a $19.00 price target.